Illumina Sees Unusually Large Options Volume (NASDAQ:ILMN)

Illumina, Inc. (NASDAQ:ILMN) saw unusually large options trading on Tuesday. Stock traders bought 5,128 put options on the stock. This represents an increase of 55% compared to the average daily volume of 3,298 put options.

Hedge Funds Weigh In On Illumina

Institutional investors and hedge funds have recently made changes to their positions in the business. Bouvel Investment Partners LLC lifted its holdings in shares of Illumina by 1.3% in the 1st quarter. Bouvel Investment Partners LLC now owns 6,547 shares of the life sciences company’s stock valued at $899,000 after acquiring an additional 84 shares during the last quarter. STF Management LP lifted its stake in shares of Illumina by 3.5% in the 4th quarter. STF Management LP now owns 2,644 shares of the life sciences company’s stock valued at $368,000 after purchasing an additional 90 shares during the last quarter. Global Retirement Partners LLC boosted its holdings in shares of Illumina by 12.3% in the 1st quarter. Global Retirement Partners LLC now owns 856 shares of the life sciences company’s stock worth $118,000 after purchasing an additional 94 shares during the period. Gulf International Bank UK Ltd boosted its holdings in shares of Illumina by 0.7% in the 1st quarter. Gulf International Bank UK Ltd now owns 13,562 shares of the life sciences company’s stock worth $1,862,000 after purchasing an additional 98 shares during the period. Finally, Clear Creek Financial Management LLC boosted its holdings in shares of Illumina by 6.3% in the 4th quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock worth $236,000 after purchasing an additional 100 shares during the period. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Up 6.1 %

NASDAQ ILMN opened at $113.17 on Thursday. The stock’s 50 day moving average is $109.11 and its 200 day moving average is $125.83. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. Illumina has a 12 month low of $89.00 and a 12 month high of $195.64. The stock has a market cap of $18.03 billion, a PE ratio of -13.89 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.05 billion. During the same period in the prior year, the firm earned $0.08 EPS. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. Research analysts predict that Illumina will post 0.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ILMN shares. Citigroup upgraded Illumina from a “neutral” rating to a “buy” rating and set a $140.00 price target for the company in a research note on Wednesday. Royal Bank of Canada cut their price target on Illumina from $249.00 to $242.00 and set an “outperform” rating for the company in a research note on Monday, July 1st. Evercore ISI cut their price target on Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a research note on Tuesday, June 11th. TD Cowen cut their price target on Illumina from $140.00 to $122.00 and set a “hold” rating for the company in a research note on Thursday, June 6th. Finally, StockNews.com started coverage on Illumina in a research note on Sunday, June 30th. They set a “buy” rating for the company. Two analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $158.57.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.